Cytokines in Systemic Sclerosis: Focus on IL-17

Baraut, Julie; Farge, Dominique; Ivan-Grigore, Elena; Verrecchia, Franck; Michel, Laurence

doi:10.5772/28595

Cited by 4 publications

(5 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The local hypoxia in SSc skin Brought to you by | MIT Libraries Authenticated Download Date | 5/10/18 7:11 PM measured by a polarographic oxygen microelectrode system is linked with raised levels of vascular endothelial growth factor (VEGF). In situ IL-4, IL-17 and MCP-1 expression were closely related to the extent of fi brosis in SSc skin and lungs [44]. Other studies reported increased in situ mRNA expression of IL-17, IL-21, IL-33 and IFN-α in SSc skin compared to healthy individuals.…”

Section: The Cytokine Pattern In Situmentioning

confidence: 69%

“…Moreover, this CD8 + T cell population was dependent on a transcription factor GATA-3, as silencing of GATA-3 with small interfering RNA signifi cantly reduced IL-13 production by CD8 + T cells, demonstrating a causal relationship between GATA-3 and IL-13 [44]. The data suggest that GATA-3 could be a novel therapeutic target in SSc, as inhibition of the central transcription factor would inhibit differentiation of naïve T cells to Th2-polarized T cells and thus diminished production of pro-fi brotic mediators and inhibit already differentiated Th2 cells from secreting IL-13 directly after differentiation.…”

Section: Cd4+ Cd8 + T Cells and Cd8 + Cellsmentioning

confidence: 99%

“…The circulating cytokines both of Th1-type (IFN-, TNF-, IL-1, IL-2, CXCL10) and of Th2-type (IL-4, IL-10, IL-13, MCP-1) are elevated in SSc patients comparing to healthy controls [23,[44][45][46]. Correlations between the serum levels of IL-6, IL-8, IL-10, B-cell activating factor (BAFF), monocyte chemoattractant chemokine (MCP)-1, sCD30 and the spread of skin fi brosis have also been reported, as higher levels were measured in dcSSc compared to lcSSc patients [47].…”

Section: The Circulating Cytokines In the Peripheral Compartmentmentioning

confidence: 99%

See 2 more Smart Citations

T Helper Cells in the Immunopathogenesis of Systemic Sclerosis – Current Trends

Kurteva¹,

Kyurkchiev²

2017

Acta Medica Bulgarica

View full text Add to dashboard Cite

show abstract

Section: The Cytokine Pattern In Situmentioning

confidence: 69%

Section: Cd4+ Cd8 + T Cells and Cd8 + Cellsmentioning

confidence: 99%

Section: The Circulating Cytokines In the Peripheral Compartmentmentioning

confidence: 99%

See 1 more Smart Citation

T Helper Cells in the Immunopathogenesis of Systemic Sclerosis – Current Trends

Kurteva¹,

Kyurkchiev²

2017

Acta Medica Bulgarica

View full text Add to dashboard Cite

show abstract

“…It has been revealed that T lymphocytes are linked to bone deterioration via IL-17 production in rheumatoid arthritis 24 . IL-17 has been demonstrated to activate epithelial, endothelial, and broblastic cells to produce IL-6, IL-8, and PGE2 52 . In addition, IL-17 stimulates RANKL production by osteoblasts 53 .…”

Section: Discussionmentioning

confidence: 99%

Involvement of Interlukin-17A (IL-17A) Gene Polymorphism and Interlukin-23 (IL-23) level in the Development of Peri-Implantitis

Talib,

Taha

2023

Preprint

View full text Add to dashboard Cite

Background Dental implantation has been practiced since ancient times and has gone through several stages. Dentists use dental implants to support dental prostheses such as crowns, bridges, dentures, face prostheses, or as an orthodontic anchor. Thus, the purpose of this study to detect the role of the immune-genetic variation of IL-17A and related inflammatory cytokine (IL-23) in the initiation and progress of peri implantitis.Material and Methods This cross-sectional study included 80 subjects (15 peri-implantitis patients, 35 successful implants, and 30 healthy controls); their mean age was (43.91 ± 11.33) years. Blood samples were collected from all subjects (patients with peri-implantitis, successful implants, and healthy controls) attending the Department of Oral and Maxillofacial Surgery in the Dental College Teaching Hospital, Baghdad University, Baghdad, Iraq. The blood sample detects gene polymorphisms in interleukin-17A by a polymerase chain reaction. An enzyme-linked immunosorbent assay was carried out to estimate the Peri-implant sulcus fluid levels of interleukin-23.Result The current study revealed an obvious significant elevation in the mean level of interleukin-23 in the peri-implantitis patient's group more than its level in the successful implant and control groups (P˂ 0.05). In addition, the result showed that A/A genotype is associated significantly with peri-implantitis OR (95%confidence interval) = 6.9 (1.7121 to 27.4638) folds increase risk of peri-implantitis) (p = 0.0065), while G/A genotype had OR 4.9 (0.9539 to 24.9394) folds increased risk of peri-implantitis, (p = 0.0572). But it was not statistically significant and G/G genotype had a one-fold increase risk of peri-implantitis.Conclusion The increased level of inflammatory cytokine (interleukin-23) might add to the systemic inflammatory burden a predisposing factor, which may lead to impaired osseointegration and subsequent bone loss or implant failure. In addition, IL-17A gene polymorphism may play a role in peri-implant disease susceptibility, especially in persons carrying the rs2275913 A allele at a higher risk of developing peri-implantitits as compared with those carrying the G allele.

show abstract

“…Although the exact role of IL-17 in fibrinogenesis remains controversial (ie. : trans-differentiation of human fibroblast into myofibroblast, collagen synthesis), Th17 cells and IL-17 production were found to be elevated in the peripheral blood, skin, and lungs from SSc patients, and to participate in and exacerbate early inflammatory responses [74][75][76]. Restoration of the Th1/Th2/Th17/Treg cytokine balance is an important goal of therapy.…”

Section: Activation Of the Innate And The Adaptive Immune Responsesmentioning

confidence: 99%

Mesenchymal stromal cells for systemic sclerosis treatment

Farge

Loisel

Lansiaux

et al. 2021

Autoimmunity Reviews

Self Cite

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a rare chronic autoimmune disease characterized by vasculopathy, dysregulation of innate and adaptive immune responses, and progressive fibrosis. SSc remains an orphan disease, with high morbity and mortality in SSC patients. The mesenchymal stromal cells (MSC) demonstrate in vitro and in vivo pro-angiogenic, immuno-suppressive, and anti-fibrotic properties and appear as a promising stem cell therapy type, that may target the key pathological features of SSc disease.This review aims to summarize acquired knowledge in the field of :1) MSC definition and in vitro and in vivo functional properties, which vary according to the donor type (allogeneic or autologous), the tissue sources (bone marrow, adipose tissue or umbilical cord) or inflammatory micro-environment in the recipient; 2) preclinical studies in various SSc animal models , which showed reduction in skin and lung fibrosis after MSC infusion; 3) first clinical trials in human, with safety and early efficacy results reported in SSc patients or currently tested in several ongoing clinical trials.

show abstract

Cytokines in Systemic Sclerosis: Focus on IL-17

Cited by 4 publications

References 49 publications

T Helper Cells in the Immunopathogenesis of Systemic Sclerosis – Current Trends

T Helper Cells in the Immunopathogenesis of Systemic Sclerosis – Current Trends

Involvement of Interlukin-17A (IL-17A) Gene Polymorphism and Interlukin-23 (IL-23) level in the Development of Peri-Implantitis

Mesenchymal stromal cells for systemic sclerosis treatment

Contact Info

Product

Resources

About